| Nov 18 |
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
|
| Nov 14 |
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
|
| Nov 13 |
Cybin reports Q2 results
|
| Nov 13 |
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
|
| Nov 6 |
Massachusetts psychedelics legalization initiative poised to fail
|
| Nov 3 |
Cybin Inc: Another High-Risk Psychedelics Play
|
| Oct 31 |
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
|
| Oct 24 |
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
|
| Oct 15 |
Cybin: Top Value Psychedelic Stock
|
| Oct 3 |
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
|
